Literature DB >> 21132072

Long lasting inhibitors of the gastric H,K-ATPase.

Jai Moo Shin1, George Sachs.   

Abstract

Proton pump inhibitors (PPIs) are acid-activated prodrugs which covalently bind to the gastric H,K-ATPase on its luminal surface. Only active pumps can be inhibited. The short plasma residence time of current PPIs prevents inhibition of pumps synthesized or activated after the PPI has disappeared, limiting the degree of acid inhibition even with BID administration. PPIs with a longer residence time should improve acid control. Various K(+) competitive inhibitors of the pump are being developed (APAs or PCABs), with the advantage of complete inhibition of acid secretion independent of pump activity. Early data on these suggest that twice a day administration would improve acid control compared to PPIs.

Entities:  

Year:  2009        PMID: 21132072      PMCID: PMC2995460          DOI: 10.1586/ecp.09.33

Source DB:  PubMed          Journal:  Expert Rev Clin Pharmacol        ISSN: 1751-2433            Impact factor:   5.045


  18 in total

1.  Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers.

Authors:  Kyung-Sang Yu; Kyun-Seop Bae; Ji-Hong Shon; Joo-Youn Cho; So-Young Yi; Jae-Yong Chung; Hyeong-Seok Lim; In-Jin Jang; Sang-Goo Shin; Keun-Seog Song; Byoung-Seok Moon
Journal:  J Clin Pharmacol       Date:  2004-01       Impact factor: 3.126

2.  Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.

Authors:  P O Katz; F K Koch; E D Ballard; R G Bagin; T C Gautille; G C Checani; D L Hogan; V S V Pratha
Journal:  Aliment Pharmacol Ther       Date:  2007-01-15       Impact factor: 8.171

Review 3.  The gastric H,K ATPase as a drug target: past, present, and future.

Authors:  George Sachs; Jai Moo Shin; Olga Vagin; Nils Lambrecht; Iskandar Yakubov; Keith Munson
Journal:  J Clin Gastroenterol       Date:  2007-07       Impact factor: 3.062

4.  Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z.

Authors:  R H Hunt; D Armstrong; M Yaghoobi; C James; Y Chen; J Leonard; J M Shin; E Lee; D Tang-Liu; G Sachs
Journal:  Aliment Pharmacol Ther       Date:  2008-04-25       Impact factor: 8.171

5.  Definition and antagonism of histamine H 2 -receptors.

Authors:  J W Black; W A Duncan; C J Durant; C R Ganellin; E M Parsons
Journal:  Nature       Date:  1972-04-21       Impact factor: 49.962

6.  The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.

Authors:  Sara Padol; Yuhong Yuan; Marroon Thabane; Ireneusz T Padol; Richard H Hunt
Journal:  Am J Gastroenterol       Date:  2006-07       Impact factor: 10.864

7.  A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis.

Authors:  Peter J Kahrilas; John Dent; Karsten Lauritsen; Peter Malfertheiner; Hans Denison; Stefan Franzén; Goran Hasselgren
Journal:  Clin Gastroenterol Hepatol       Date:  2007-10-22       Impact factor: 11.382

8.  Clinical trial: intragastric acid control in patients who have Barrett's oesophagus--comparison of once- and twice-daily regimens of esomeprazole and lansoprazole.

Authors:  S J Spechler; P N Barker; D G Silberg
Journal:  Aliment Pharmacol Ther       Date:  2009-04-29       Impact factor: 8.171

9.  Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates.

Authors:  M Romano; M R Iovene; M I Russo; A Rocco; R Salerno; D Cozzolino; A P Pilloni; M A Tufano; D Vaira; G Nardone
Journal:  J Clin Pathol       Date:  2008-08-28       Impact factor: 3.411

10.  Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526).

Authors:  Keiichi Ito; Kazuya Kinoshita; Atsuyuki Tomizawa; Fumi Inaba; Yuka Morikawa-Inomata; Mitsuko Makino; Keiichi Tabata; Nobuhiko Shibakawa
Journal:  J Pharmacol Exp Ther       Date:  2007-07-13       Impact factor: 4.030

View more
  11 in total

1.  Will Proton Pump Inhibitors Increase the Risk of Diabetes Mellitus? A Systemic Review and Meta-Analysis.

Authors:  Yue Chen; Lei Hu; Chenyu Sun; Jiantong Bao; Jie Liu; Chandur Bhan; Keun Young Kim; Raveena Manem; Pratikshya Thapa; Shaodi Ma; Mengqing Liu; Xingyu Cheng; Ce Cheng; Qin Zhou
Journal:  Turk J Gastroenterol       Date:  2022-06       Impact factor: 1.555

2.  The Effect of Food on the Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan.

Authors:  Darcy J Mulford; Eckhard Leifke; Mark Hibberd; Colin W Howden
Journal:  Clin Pharmacol Drug Dev       Date:  2021-08-24

3.  Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance.

Authors:  Hiroshi Matsumoto; Akiko Shiotani; Ryo Katsumata; Minoru Fujita; Rui Nakato; Takahisa Murao; Manabu Ishii; Tomoari Kamada; Ken Haruma; David Y Graham
Journal:  Dig Dis Sci       Date:  2016-09-22       Impact factor: 3.199

4.  The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.

Authors:  Sho Suzuki; Takuji Gotoda; Chika Kusano; Kunio Iwatsuka; Mitsuhiko Moriyama
Journal:  Am J Gastroenterol       Date:  2016-05-17       Impact factor: 10.864

5.  Efficacy, safety, and tolerability of pantoprazole magnesium in the treatment of reflux symptoms in patients with gastroesophageal reflux disease (GERD): a prospective, multicenter, post-marketing observational study.

Authors:  José María Remes-Troche; Sergio Sobrino-Cossío; Julio César Soto-Pérez; Oscar Teramoto-Matsubara; Miguel Morales-Arámbula; Antonio Orozco-Gamiz; José Luis Tamayo de la Cuesta; Gualberto Mateos
Journal:  Clin Drug Investig       Date:  2014-02       Impact factor: 2.859

6.  Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects.

Authors:  H Jenkins; Y Sakurai; A Nishimura; H Okamoto; M Hibberd; R Jenkins; T Yoneyama; K Ashida; Y Ogama; S Warrington
Journal:  Aliment Pharmacol Ther       Date:  2015-02-23       Impact factor: 8.171

7.  Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects.

Authors:  Woo Yul Lee; EunSil Oh; Mengqi Cui; Choon Ok Kim; Yeji Lim; Hunam Kim; Hyeonsoo Park; Sukyong Yoon; Min Soo Park; Taegon Hong
Journal:  Transl Clin Pharmacol       Date:  2020-03-31

8.  Distribution- and Metabolism-Based Drug Discovery: A Potassium-Competitive Acid Blocker as a Proof of Concept.

Authors:  Ming-Shu Wang; Yi Gong; Lin-Sheng Zhuo; Xing-Xing Shi; Yan-Guang Tian; Chang-Kang Huang; Wei Huang; Guang-Fu Yang
Journal:  Research (Wash D C)       Date:  2022-07-22

9.  The use of proton pump inhibitors decreases the risk of diabetes mellitus in patients with upper gastrointestinal disease: A population-based retrospective cohort study.

Authors:  Hsiu-Chen Lin; Yu-Ting Hsiao; Hsiu-Li Lin; Yow-Shieng Uang; Hui-Wen Cheng; Ying Wang; Li-Hsuan Wang
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

10.  Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease.

Authors:  Yasuhiko Gotoh; Emiko Ishibashi; Shunichiro Honda; Tomohisa Nakaya; Chishio Noguchi; Koichi Kagawa; Kazunari Murakami
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.